Dr Miranda Morton
Dr Nina Wilson
Tara Homer
Laura Simms
Dr Alison Steel
et al. | Dual bronchodilators in Bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis | 2023 |
|
Dr Arthur Pratt
Dr Stefan Siebert
Mike Cole
Dr Deborah Stocken
Amy Cranston
et al. | Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial | 2021 |
|
Dr Stefan Siebert
Dr Arthur Pratt
Dr Deborah Stocken
Dr Miranda Morton
Amy Cranston
et al. | Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial | 2020 |
|
Dr Emma Clark
Dr Miranda Morton
Shriya Sharma
Dr Holly Fisher
Denise Howel
et al. | Prostate cancer androgen receptor splice variant 7 biomarker study - A multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol | 2019 |
|
Dr Miranda Morton
Dr Yvette Drew
Professor Nicola Curtin
| PARP | 2017 |
|
Dr Ashleigh Herriott
Dr Miranda Morton
Professor Nicola Curtin
| Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers | 2017 |
|
Dr Nicola Wyatt
Dr Linda Hogarth
Dianne Turner
Dr Miranda Morton
Dr David Jamieson
et al. | Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) | 2016 |
|
Iaroslava Kos
Dr Miranda Morton
Dr Alessandra Da Silva Dantas
Professor Janet Quinn
| Mechanisms underlying the delayed activation of the Cap1 transcription factor in Candida albicans following combinatorial oxidative and cationic stress important for phagocytic potency | 2016 |
|
Professor Alastair Greystoke
Dr Linda Hogarth
Dr Miranda Morton
Liam Bolt
Dianne Turner
et al. | The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained | 2016 |
|
Fiona Middleton
Dr Miranda Morton
Dr Claire Elstob
Dr Sarah Fordham
Dr Ashleigh Herriott
et al. | Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition | 2015 |
|
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Morton
et al. | PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia | 2015 |
|
Dr Miranda Morton
Dr Ian Forrest
Becci Sharrock
Maria Lane
Dr Angelika Kaufmann
et al. | Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples | 2014 |
|
Dr Miranda Morton
Professor Janet Quinn
| Mechanisms Underlying the Exquisite Sensitivity of Candida albicans to Combinatorial Cationic and Oxidative Stress That Enhances the Potent Fungicidal Activity of Phagocytes | 2014 |
|
James Murray
Huw Thomas
Philip Berry
Suzanne Kyle
Dr Miranda Morton
et al. | Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules | 2014 |
|
Dr Miranda Morton
Professor Nicola Curtin
| Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies | 2013 |
|
